Multi-Step Usage of in vivo Models during Rational Drug Design and Discovery
News Aug 03, 2011
Although the process of drug development today has been accelerated by emergence of computational methodologies, it is a herculean challenge requiring exorbitant resources; and often fails to yield clinically viable results. The current paradigm of target based drug design is often misguided and tends to yield compounds that have poor absorption, distribution, metabolism, and excretion, toxicology (ADMET) properties. Therefore, an in vivo organism based approach allowing for a multidisciplinary inquiry into potent and selective molecules is an excellent place to begin rational drug design. We will review how organisms like the zebrafish and Caenorhabditis elegans can not only be starting points, but can be used at various steps of the drug development process from target identification to pre-clinical trial models. This systems biology based approach paired with the power of computational biology; genetics and developmental biology provide a methodological framework to avoid the pitfalls of traditional target based drug design.
The article Is published online in the International Journal of Molecular Sciences and is free to access.
With cybersecurity one of the nation's top security concerns and billions of people affected by breaches last year, government and businesses are spending more time and money defending against it. Researchers at the Army's corporate research laboratory, in collaboration with Towson University, may have identified a new way to improve network security.